Alkali-extractable mycelial polysaccharide (Al-MPS) is a natural macromolecular polymer that has shown anti-hyperlipidemic and antitumor abilities. This study investigates the mechanism by which Al-MPS inhibits lipid metabolism and epithelial-mesenchymal transition (EMT) in breast cancer (BC). BC cells (MCF-7 and MDA-MB-231) were transfected and/or treated with Al-MPS. CCK-8, Transwell, and scratch assays were used to evaluate the tumorigenic behaviors of BC cells. The expression levels of SREBP1, E-cadherin, N-cadherin, Snail, vimentin, FASN, ACLY, and ACECS1 in BC cells were detected by Western blotting. Dual-luciferase reporter and RNA pull-down assays were performed to verify the binding between miR-215-5p and SREBP1 mRNA. Nude mice were injected with MDA-MB-231 cells and treated with Al-MPS. The changes in tumor volume and protein expression were monitored. miR-215-5p was downregulated and SREBP1 was upregulated in BC. Al-MPS increased miR-215-5p expression and inhibited SREBP1 expression, lipid metabolism, and EMT in BC. Inhibition of miR-215-5p or overexpression of SREBP1 promoted the tumorigenic behaviors of BC cells by stimulating lipid metabolism and counteracted the antitumor effect of Al-MPS. SREBP1 was a downstream target of miR-215-5p. In conclusion, Al-MPS inhibits lipid metabolism and EMT in BC via the miR-215-5p/SREBP1 axis. This study supports the application of polysaccharides in cancer treatment and the molecules regulated by Al-MPS may be used as biomarkers or therapeutic targets for BC.
Background: The accuracy of traditional clinical methods for assessing the metastatic status of axillary lymph nodes (ALNs) is unsatisfactory. In this study, the authors propose the use of radiomic technology and three-dimensional (3D) visualization technology to develop an unsupervised learning model for predicting axillary lymph node metastasis in patients with breast cancer (BC), aiming to provide a new method for clinical axillary lymph node assessment in patients with this disease. Methods: In this study, we retrospectively analyzed the data of 350 patients with invasive BC who underwent lung-enhanced computed tomography (CT) and axillary lymph node dissection surgery at the Department of Breast Surgery of the Second Xiangya Hospital of Central South University. The authors used 3D visualization technology to create a 3D atlas of ALNs and identified the region of interest for the lymph nodes. Radiomic features were subsequently extracted and selected, and a prediction model for ALNs was constructed using the K-means unsupervised algorithm. To validate the model, the authors prospectively collected data from 128 BC patients who were clinically evaluated as negative at our center. Results: Using 3D visualization technology, we extracted and selected a total of 36 CT radiomics features. The unsupervised learning model categorized 1737 unlabeled lymph nodes into two groups, and the analysis of the radiomic features between these groups indicated potential differences in lymph node status. Further validation with 1397 labeled lymph nodes demonstrated that the model had good predictive ability for axillary lymph node status, with an area under the curve of 0.847 (0.825–0.869). Additionally, the model’s excellent predictive performance was confirmed in the 128 axillary clinical assessment negative cohort (cN0) and the 350 clinical assessment positive (cN+) cohort, for which the correct classification rates were 86.72 and 87.43%, respectively, which were significantly greater than those of clinical assessment methods. Conclusions: The authors created an unsupervised learning model that accurately predicts the status of ALNs. This approach offers a novel solution for the precise assessment of ALNs in patients with BC.
1 August 2021 in Journal of Investigative Medicine
This study investigated the influences of EphA10 and Gli3 on breast cancer (BC) cell proliferation, invasion and migration. Immunohistochemistry was used to reveal the expressions of EphA10 and Gli3 in 18 intraductal carcinomas, 124 invasive carcinomas, 50 paracancerous tissues (2 cm away from the tumor, when possible or available), 50 lobular hyperplastic tissues and 30 normal breast tissues. qRT-PCR and Western blotting were applied to detect the expressions of EphA10 and Gli3 in invasive BC cells (MDA-MB-231, BT20 and Hs578T) and normal human mammary epithelial cells (MCF10A). MDA-MB-231 and BT20 cells were transfected with sh-EphA10, sh-Gli3 or sh-EphA10+sh-Gli3. CCK-8 was used to test the proliferation of transfected MDA-MB-231 and BT20 cells. Transwell and scratch assays were used for evaluation of invasion and migration of the transfected cells. EphA10 and Gli3 were highly expressed in invasive carcinomas and invasive BC cells. The expressions of EphA10 and Gli3 were associated with the clinicopathological characteristics and poor prognosis of patients with invasive BC. Knockdown of EphA10 or Gli3 suppressed activities of BC cells. Knockdown of both EphA10 and Gli3 was more effective than knockdown of Gli3 alone. Taken together, coexpression of EphA10 and Gli3 promotes BC cell proliferation, invasion and migration.
Background: Peroxiredoxin 6 (PRDX6) scavenges reactive oxygen species (ROS) and plays a key role in antioxidant defense. Although PRDX6 is involved in various cancers, its role in breast cancer (BRCA) remains unclear. Methods: Cell proliferation was assessed using CCK‐8, EdU staining, and colony formation assays. Migration and invasion were evaluated via wound‐healing and transwell assays. ROS levels and mitochondrial membrane potential were measured by fluorescence microscopy or flow cytometry. Oxidative phosphorylation (OXPHOS) activity was determined by ATP production and NAD + /NADH ratio. Mitochondria were visualized by TEM, and mitochondrial complex subunits were detected by quantitative real‐time PCR and Western blotting. In vivo effects were evaluated using a xenograft tumor model. Results: Although PRDX6 was downregulated in BRCA overall, it showed elevated expression in aggressive subtypes and advanced‐stage tumors, correlating with poor prognosis. Overexpression of PRDX6 enhanced BRCA cell proliferation, migration, and invasion. PRDX6 reduced ROS levels, upregulated mitochondrial transcription factor A (TFAM) expression, and promoted mitochondrial complex subunit expression and OXPHOS. Inhibition of TFAM led to a decrease in the expression of some of the mitochondrial complex subunits, which reversed the pro‐carcinogenic phenotype of the tumor. PRDX6 also promoted tumor growth in vivo. Conclusion: PRDX6 maintains intracellular homeostasis by reducing ROS and promotes mitochondrial biogenesis and OXPHOS through TFAM‐dependent and ‐independent pathways, driving BRCA progression.
Immune checkpoint blockade (ICB) has improved outcomes for patients with triple‐negative breast cancer (TNBC), yet resistance remains widespread and its molecular basis is not fully understood. Through single‐cell RNA sequencing (scRNA‐seq) of paired pre‐ and post‐treatment tumor samples from patients who failed to achieve pathological complete response (non‐pCR) after neoadjuvant PD‐1 therapy, we identified a marked upregulation of interleukin‐27 receptor subunit alpha (IL27RA) in malignant epithelial cells within residual lesions. Integration with scRNA‐seq profiles from an independent cohort of three pCR patients showed that this IL27RA upregulation in malignant epithelium is largely restricted to non‐pCR residual tumors, and high IL27RA expression correlated with poor survival in TNBC cohorts. Mechanistically, IL27RA suppresses MHC‐I expression by activating the PI3K/AKT pathway—rather than the classical IL‐27/STAT axis—thereby impairing CD8⁺ T‐cell cytotoxic function. Inhibition of AKT reversed this phenotype and restored antigen‐specific killing. In orthotopic tumor models, mimicking systemic loss of Il27ra significantly reduced tumor growth and prolonged survival in immunocompetent mice, with single‐cell profiling indicating enhanced intratumoral T‐cell and NK‐cell effector activity. Collectively, our findings identify an epithelial‐intrinsic IL27RA–PI3K/AKT–MHC‐I axis as a central driver of immune evasion and ICB resistance in TNBC and support IL27RA as a promising therapeutic target for overcoming immunotherapy resistance.